-
Courier Over $2 billion! Roche has once again partnered with Jnana to develop small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases
Time of Update: 2023-01-06
Original English text: _mstmutation="1" _msthash="220729" _msttexthash="27901354"> November 15, Jnana Therapeutics announced that it has entered into a second collaboration and licensing agreement with Roche to discover small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases.
-
Courier Over $2 billion! Roche has once again partnered with Jnana to develop small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases
Time of Update: 2023-01-06
Original English text: _mstmutation="1" _msthash="220729" _msttexthash="27901354"> November 15, Jnana Therapeutics announced that it has entered into a second collaboration and licensing agreement with Roche to discover small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases.
-
A diagnostic biomarker that can identify fatal brain diseases with high accuracy
Time of Update: 2023-01-05
and Joanne Knight Distinguished Professor of Neurology — used the technique to look for a unique form of tau protein associated with primary psoriasis 。 To ensure accurate classification of the study subjects, Horie Sato and Bateman collaborated with co-authors Adam Boxer, M.
-
Immunotherapy recruits: blocking the KIR2DL5/PVR immunosuppressive pathway to trigger NK cell-mediated anti-tumor immunity
Time of Update: 2022-11-25
Instead of summoning T cells to fight cancer, the Einstein School of Medicine research team looked at different human immune cells known as natural killer cells (NK), and achieved promising results 。 "We believe that the novel immunotherapies we have developed have great potential to enter clinical trials involving various types of cancer," said Xingxing Zang, Ph. D.
-
Let's take a look at the magnificent history of the struggle between human beings and cancer, which is worth collecting
Time of Update: 2022-11-25
"Radiation therapy cured Hodgkin's disease SixPolitical action related to the war on cancerBuoyed by early chemotherapy victories, cancer prevention and control advocates, led by Lasker and Farber, urged the U.
-
Chemicals in the environment increase the risk of inflammatory bowel disease
Time of Update: 2022-10-25
"It is well known that environmental factors are as important as genetic factors in influencing autoimmune and inflammatory diseases, but we lack a method or platform to systematically determine the effects of chemical candidates on inflammation," said corresponding author Francisco Quintana, PhD, a researcher at the Brigham Ann Romney Center for Neurological Disorders, whose lab previously studied the environmental determinants of neurodegeneration.
-
Awaken "dormant" cells to fight cancer
Time of Update: 2022-10-01
Image credit: UNIGE/Rastine Merat Image: Targeted inhibition of DAPKs (death-associated protein kinases 1 and 3) reduces the proportion of slow-proliferating/senile-like HuRLow cells, as well as the adaptive response of the entire melanoma cell population to BRAF inhibition.
-
Bristol-Myers Squibb reaches cooperation with US$1.9 billion to promote the development of regulatory T cell therapy
Time of Update: 2022-08-20
▎Edited by WuXi AppTec Content TeamGentiBio today announced a collaboration with Bristol-Myers Squibb (BMS) to co-develop novel engineered regulatory T cells (Treg) to help rebuild immune tolerance and repair tissue in patients with inflammatory bowel disease (IBD) .
-
Hong Kong stocks CRO concept sector changes, many stocks closed up more than 7
Time of Update: 2022-08-15
As of the close, Zhaoyan New Drug rose by the daily limit, with an increase of 10%, WuXi Biologics rose by more than 8%, GenScript Biotechnology, Kay Laying rose more than 7%, Tiger Pharmaceuticals, WuXi PharmaTech and others followed suit [Pharmaceutical Network Pharmaceutical Stock Market] On July 4, the CRO concept sector of Hong Kong stocks changed, and many stocks rose significantly.
-
There is a cure
Time of Update: 2022-08-15
Zhijiang Bio said at the performance briefing that the company's monkeypox virus nucleic acid detection kit has recently received orders from Portugal, Spain, the Czech Republic, the United Arab Emirates and other overseas countries, as well as some domestic customs, disease control emergency reserves and scientific research.
-
Industry heavyweight: Boshengji publishes long-term follow-up data of autologous CD7-CAR-T therapy in the treatment of r/r T-ALL/LBL
Time of Update: 2022-06-05
The results of the long-term follow-up data of the PA3-17 injection-related study are gratifying, indicating that the product candidate is expected to become a potential CAR-T cell monotherapy .
-
Generic drug market continues to grow, localized production is in the ascendant
Time of Update: 2022-05-15
Most clinical drugs rely on imports According to statistics, there are about 400 drug manufacturers in sub-Saharan Africa, mainly located in South Africa, Nigeria, Kenya, Ghana, Ethiopia and other countries, of which the number of API manufacturers is very small.
-
Fosfomycin tromethamine powder, a subsidiary of Northeast Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2022-05-03
On the evening of February 10, Northeast Pharmaceuticals announced that its wholly-owned subsidiary, No.
It has passed the consistency evaluation of generic drugs .
Fosfomycin tromethamine powder is suitable for the treatment of acute simple urinary tract infection caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis etc.
-
GLP-1RA helps to achieve strong sugar control and safety standards
Time of Update: 2022-04-26
Studies have shown that for every 1% reduction in glycated hemoglobin (HbA1c), the risk of diabetic microvascular and macrovascular complications is significantly reduced [2] .
Figure 1 Semaglutide is effective in lowering blood sugar, significantly reducing HbA1c by 1.
-
"Immunity" new target for colon cancer immunotherapy
Time of Update: 2022-04-21
Scientists at the University of Dresden, led by Professor Sebastian Zeissig , have now discovered a protein that holds promise as a target for new immunotherapies to treat colon cancer .
The researchers analyzed colon cancer samples and looked for signaling proteins that were present in tumor cells but not in healthy tissue .
